Warburg Effect-Promoted Exosomal Circ_0072083 Releasing Up-Regulates Nango Expression Through Multiple Pathways and Enhances Temozolomide Resistance in Glioma

Chenyu Ding
First Affiliated Hospital of Fujian Medical University

Xuehan Yi
Fujian Medical University Union Hospital

Xiangrong Chen
Second Affiliated Hospital of Fujian Medical University

Zanyi Wu
Fujian Medical University

Honghai You
The First Affiliated Hospital of Fujian Medical University

Xiaoyong Chen
The First Affiliated Hospital of Fujian Medical University

Gaoqi Zhang
Henan University People’s Hospital

Yong Sun
Zhengzhou University People's Hospital

Xingyao Bu
Zhengzhou University People's Hospital

Xiyue Wu
The First Affiliated Hospital of Fujian Medical University

Zhangya Lin
The First Affiliated Hospital of Fujian Medical University

Jianjun Gu (✉ gujianjundt@163.com)
Henan University

Yuanxiang Lin
The First Affiliated Hospital of Fujian Medical University

Dezhi Kang
The First Affiliated Hospital of Fujian Medical University
Keywords: Glioma, Exosome, Temozolomide, Hsa_circ_0072083, miR-1252-5p, NANOG

DOI: https://doi.org/10.21203/rs.3.rs-135612/v1

License: ☛ ☀ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Temozolomide (TMZ) resistance limits its application in glioma. Exosome can carry circular RNAs (circRNAs) to regulate drug resistance via sponging microRNAs (miRNAs). miRNAs can control mRNA expression by regulate the interaction with 3'UTR and methylation. Nanog homeobox (NANOG) is an important biomarker for TMZ resistance. Hitherto, it is unknown about the role of exosomal hsa_circ_0072083 (circ_0072083) in TMZ resistance in glioma, and whether it is associated with NANOG via regulating miRNA sponge and methylation.

Methods

TMZ-resistant (n=36) and sensitive (n=33) patients were recruited. The sensitive cells and constructed resistant cells were cultured and exposed to TMZ. circ_0072083, miR-1252-5p, AlkB homolog H5 (ALKBH5) and NANOG levels were examined via quantitative reverse transcription polymerase chain reaction and western blot. The half maximal inhibitory concentration (IC50) of TMZ, cell proliferation, apoptosis, migration and invasion were analyzed via Cell Counting Kit-8, colony formation, flow cytometry, wound healing and transwell assays. The in vivo function was assessed using xenograft model. The N6-methyladenosine (m6A) level was analyzed via methylated RNA immunoprecipitation (MeRIP). Target relationship was investigated via dual-luciferase reporter assay and RNA immunoprecipitation. Warburg effect was investigated via lactate production, glucose uptake and key enzymes expression. Exosome was isolated and confirmed via transmission electron microscopy and specific protein expression.

Results

circ_0072083 expression was increased in TMZ-resistant glioma tissues and cells. circ_0072083 knockdown restrained the resistance of resistant cells via decreasing IC50 of TMZ, proliferation, migration, invasion and xenograft tumor growth and increasing apoptosis. circ_0072083 silence reduced NANOG expression via blocking ALKBH5-mediated demethylation. circ_0072083 could regulate NANOG and ALKBH5 via targeting miR-1252-5p to control TMZ resistance. Warburg effect promoted the release of exosomal circ_0072083 in resistant cells. Exosomal circ_0072083 from resistant cells increased the resistance of sensitive cells to TMZ in vitro and xenograft model. Exosomal circ_0072083 level was enhanced in resistant patients, and it had a diagnostic value and indicated a lower overall survival in glioma.

Conclusion

Exosomal circ_0072083 promoted TMZ resistance via increasing NANOG via regulating miR-1252-5p-mediated degradation and demethylation in glioma.
Highlights

1. hsa_circ_0072083 expression is increased and hsa_circ_0072083 knockdown decreases TMZ resistance in glioma.

2. hsa_circ_0072083 controls NANOG expression by regulating miR-1252-5p-mediated degradation and methylation via targeting ALKBH5.

3. The secretion of exosomal hsa_circ_0072083 is dependent on Warburg effect.

4. Exosomal hsa_circ_0072083 is associated resistance development.

Background

Glioma is a type of primary brain tumor with poor prognosis [1]. Chemotherapy is one of the main therapeutic strategies, and temozolomide (TMZ), an oral alkylating agent, is widely accepted as an option for chemotherapy of glioma of all grades [2]. TMZ treatment significantly increases the survival of patients, while the development of resistance limits its efficacy in clinic [3]. Hence, exploring the mechanism of TMZ resistance development in glioma is of importance.

The enrichment of extracellular vesicles with cargoes is to respond to TMZ treatment in glioma [4]. Exosome is a common type of extracellular vesicles with nanostructures, which can carry the cargos like noncoding RNAs to participate in the development and treatment of glioma [5, 6]. Circular RNAs (circRNAs) are a class of noncoding RNAs mainly formed via connection of the downstream and upstream exons, which have important roles in glioma [7]. Lots of circRNAs are dysregulated, and they can interact with microRNA (miRNA)/mRNA axes to be involved in tumorigenesis of glioma [8]. Moreover, exosomes can transfer circRNAs to control TMZ resistance in glioma, such as circRNA nuclear factor I X (circNFIX) and homeodomain interacting protein kinase 3 (circHIPK3) [9, 10]. CircRNA hsa_circ_0072083 (circ_0072083) is derived from zinc finger RNA binding protein (ZFR), which may play a promoting or suppressive role in human tumors, such as gastric cancer and papillary thyroid cancer [11, 12]. However, whether circ_0072083 can be transferred via exosomes and its function on TMZ resistance in glioma are unknown.

miRNAs are a type of noncoding RNAs (~22 nucleotides) that can control mRNA degradation via pairing of 2-8 nucleotides of their sequence to the 3’untranslated region (UTR) of mRNA, which are related to the development and TMZ resistance in glioma [13, 14]. miR-1252-5p is an anti-tumor miRNA in human tumor such as non-small cell lung cancer and papillary thyroid cancer [15, 16], and this miRNA is associated with drug resistance like paclitaxel in ovarian cancer [17]. Nevertheless, the role and mechanism of miR-1252-5p in TMZ resistance in glioma remain unclear. Nanog homeobox (NANOG) is a key stemness marker, which regulates tumor development [18]. NANOG contributes to tumor cell growth and TMZ resistance in glioma [19, 20]. N6-methyladenosine (m6A) is a common mRNA modification, and it is involved in the regulation of noncoding RNAs on tumorigenesis [21]. AlkB homolog H5 (ALKBH5) is a representative m6A
demethylase which can lead to the demethylation of mRNA in human disease[22]. ALKBH5 maintains
tumorigenicity of glioma stem-like cells[23]. Furthermore, a previous report suggests that ALKBH5 can
control NANOG expression via regulating m6A demethylation[24]. Bioinformatics analysis displays miR-
1252-5p might interact with circ_0072083, NANOG and ALKBH5 using Circinteractome
(http://circinteractome.nia.nih.gov) and starBase (http://starbase.sysu.edu.cn). However, their interaction
in glioma is not reported in the current study.

In this research, we aimed to study the function of exosomal circ_0072083 on TMZ resistance, and
explore the regulatory network of circ_0072083/miR-1252-5p/ NANOG via competitive sponge and
ALKBH5-mediated demethylation pathways in glioma. This study might provide new insight into the
mechanism of TMZ resistance in glioma.

Materials And Methods

Patients and samples

Authorized via the Ethics Committee of First Affiliated Hospital of Fujian Medical University and the
Ethics Committee of Henan Provincial People's Hospital, glioma patients received TMZ medication (75
mg/m2 once a day via intravenous injection) before surgery were recruited. The TMZ-resistant patients
were those with progressive disease or recurrent disease within 6 months after the chemotherapy; while
the TMZ-sensitive patients indicated those with recurrence > 6 months or no recurrence. TMZ-resistant
patients (n=36) and sensitive patients (n=33) were recruited from First Affiliated Hospital of Fujian
Medical University and Henan Provincial People's Hospital, and they all provided the informed written
consent. The clinical formation of patients was shown in Table 1. The tumor tissues from resistant or
sensitive patients were determined via two experienced pathologists and frozen in liquid nitrogen. The
serum samples were also collected from all patients by centrifugation at 1600 g for 10 min, and used for
exosome isolation. A 36-months follow-up was performed for analysis of overall survival. This research
was in line with the Helsinki Declaration.

MGMT promotor methylation

O6-methylguanine-DNA methyltransferase (MGMT) is responsible for TMZ resistance, and MGMT
promoter hypermethylation is a negative factor of TMZ resistance via promoting TMZ response by
inducing MGMT silencing in glioma [25]. The level of MGMT promotor methylation was analyzed
following the instruction of a previous report[26]. Based on the MTGT promotor sequence (GenBank
number: X61657.1), the primer pairs (5'-TTTGTGTATGTTTGTAGGTGTGTTTGTTGT-3' and 5'-
AACTCCACACTCTTCCAAAAACAAAACA-3' for unmethylated MGMT; 93 bp) and (5'-
TTTCGACGTTCGTTCGATC-3' and 5'-GAAACGAAACG-3' for methylated MGMT; 81
bp) were designed and generated via Sangon (Shanghai, China). DNA from TMZ-resistant or sensitive
tissues was isolated, and used for PCR response. The PCR was performed with the procedure: 95°C for 12
min, and 40 cycles of 95°C for 15 s, 59°C for 30 s and 72°C for 30 s, followed via 72°C for 5 min. The PCR
product was suffered from 2% agarose gel electrophoresis, and the methylated MGMT was determined
via the visualized product using the methylated primer. The proportion of MGMT promoter methylation was expressed as methylated MGMT / (methylated MGMT + unmethylated MGMT) × 100%.

Cell culture and establishment of TMZ-resistant cell lines

The glioma cell lines (U251 and U87), and 293T cells were purchased from Procell(Wuhan, China), and maintained in Dulbecco's Modified Eagle's Medium (Thermo Fisher Scientific, Waltham, MA, USA) with 10% fetal bovine serum (Gibco, Gran Island, NY, USA) and 1% penicillin/streptomycin (Beyotime, Shanghai, China) at 5% CO₂ and 37°C. The medium was changed every 3 days.

The resistant cells were established according to a previous study with some modifications[27]. U251 and U87 cells (2 × 10⁵) were continuously exposed to increasing concentrations of TMZ (Selleck, Shanghai, China) until resistance to 50 μg/mL TMZ. The established TMZ-resistant cell lines were designated as U251/TR and U87/TR.

RNA extraction and quantitative reverse transcription polymerase chain reaction (qRT-PCR)

RNA from tissues or cells was isolated using Trizol (Vazyme, Nanjing, China). The RNA in nucleus or cytoplasm was extracted with a Cytoplasmic & Nuclear RNA Purification kit (Norgen Biotek, Thorold, Canada). The exosomal RNA was prepared via using Exosome Purification and RNA Isolation kit (AmyJet Scientific, Wuhan, China). circRNA was purified via digesting the linear RNA using RNase R (Geneseed, Guangzhou, China). 1 μg RNA was used to complementary DNA synthetization using the miRNA Reverse Transcriptase kit or M-MLV Reverse Transcriptase kit (Thermo Fisher Scientific). The complementary DNA was mixed with SYBR (TaKaRa, Otsu, Japan) and specific primers (Sangon) for qRT-PCR. The procedure was set as: 95°C for 5min, and 40 cycles of 95°C for 10 s, 58°C for 30 s and 72°C for 1 min. The primer sequences were displayed in Table 2. U6 or 18s rRNA functioned as a normalized reference. Relative RNA level was analyzed via 2⁻ΔΔCt method.

Circular structure of circRNA analysis

The circular of circ_0072083 was predicted via CircView (http://gb.whu.edu.cn/CircView/).

The circular structure of circRNA was analyzed via treatment of Actinomycin D and RNase R. 5 × 10⁵ U251/TR and U87/TR cells were challenged via 2 μg/mL Actinomycin D (Sigma, St. Louis, MO, USA) for 0, 6, 12 or 24 h. Next, RNA was isolated, and circ_0072083 and ZFR levels were detected via qRT-PCR.

For analysis of RNase R, the isolated RNA was incubated with 4 U/μg RNase R for 30 min. Then circ_0072083 and ZFR levels were detected via qRT-PCR.

Cell transfection

Small interfering RNA (siRNA) for circ_0072083 (si-circ_ circ_0072083#1, si- circ_0072083#2 and si-circ_0072083#3), siRNA negative control (si-NC), short hairpin RNA (shRNA) for circ_0072083 (sh-
circ_0072083), shRNA for ALKBH5 (sh-ALKBH5), shRNA negative control (sh-NC), miR-1252-5p mimic, mimic negative control (miR-NC), miR-1252-5p inhibitor (anti-miR-1252-5p), and inhibitor negative control (anti-NC) were generated via Ribobio (Guangzhou, China). The oligonucleotide sequences were exhibited in Table 3. Cell transfection was performed into U251/TR and U87/TR cells via Lipofectamine 3000 (Thermo Fisher Scientific) for 24 h.

**Cell Counting Kit-8 (CCK-8)**

The half maximal inhibitory concentration (IC50) of TMZ and cell proliferation were investigated via CCK-8. For detection of IC50 of TMZ, $1 \times 10^4$ cells were placed into 96-well plates, and exposed to different doses (0, 6.25, 12.5, 25, 50, 100, 200, 400 and 800 $\mu$g/mL) of TMZ for 24 h. Next, 10 $\mu$L CCK-8 (Solarbio, Beijing, China) was added into each well, and cells were cultured for 3 h. The optical density (OD) value was detected at 450 nm using a microplate reader (Bio-Rad, Hercules, CA, USA). Cell viability was normalized to the control group (0 $\mu$g/mL of TMZ), and the IC50 of TMZ was determined according to the viability curve.

For analysis of cell proliferation, $1 \times 10^4$ cells were added into the 96-well plates, and incubated with 50 $\mu$g/mL of TMZ for 24, 48 or 72 h. At each time point, 10 $\mu$L CCK-8 was injected, and cells were incubated for 3 h. The OD value at 450 nm was determined through a microplate reader.

**Colony formation analysis**

The colony ability was analyzed via colony formation analysis. 500 cells were inoculated into 6-well plates and incubated with 50 $\mu$g/mL of TMZ. After 10 days, the clones were xed and stained with 0.5% crystal violet (Solarbio). Next, colony formation was imaged and the number was calculated.

**Flow cytometry**

Cell apoptosis was detected with an Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (Sigma). $2 \times 10^5$ cells were added into 12-well plates and cultured in medium containing 50 $\mu$g/mL of TMZ for 72 h. Subsequently, cells were harvested and interacted with Annexin V binding buffer, followed by dyeing to 10 $\mu$L Annexin V-FITC and propidium iodide (PI) for 5 min. Cells were examined with a flow cytometer (Beckman Coulter, Brea, CA, USA). The percentage of apoptotic cells (Annexin V-FITC+ and PI+/−) was calculated.

**Wound healing and transwell analyses**

Cell migration and invasion were analyzed via wound healing and transwell analyses. For wound healing analysis, $2 \times 10^5$ cells were added into 6-well plates, and grown to 90% confluence. Then a straight wound was induced using a 200-$\mu$L pipette tips, and cells were incubated with medium containing 50 $\mu$g/mL of TMZ for 24 h. The images were recorded at 0 and 24 h under a 100 × magnification.
microscope (Olympus, Tokyo, Japan). The wound healing ratio was expressed as (wound width at 0 h – wound width at 24 h)/wound width at 0 h × 100%.

For transwell migration analysis, 24-well transwell chambers (Corning Inc., Corning, NY, USA) with a fibronectin-coated polycarbonate membrane were used. 1 × 10^5 cells were cultured in serum-free medium and added into the upper chambers. 500 μL medium containing 10% serum was added to the lower chambers. After treatment of 50 μg/mL of TMZ for 24 h, cells passed the membrane were fixed and dyed with 0.5% crystal violet. Cells were imaged under a 100 × magnification microscope, and cell number was calculated using Image J v1.8 (NIH, Bethesda, MD, USA). For transwell invasion analysis, the transwell chambers were precoated via Matrigel (Solarbio). 5 × 10^5 cells were inoculated into the upper chambers, and the other procedures were same to migration analysis.

**Animal experiment**

The animal experiments were approved via the Animal Ethics Committee of the Animal Ethical Committee of Henan Provincial People's Hospital. The BALB/c nude mice (male, 5-week-old) were purchased from Vital River (Beijing, China), and maintained in a specific condition. U251/TR cells (2 × 10^6 per mouse) with stable transfection of sh-circ_0072083 or sh-NC were subcutaneously injected into mice. After 7 days, mice were intraperitoneally injected with 20 mg/kg TMZ or equal volume of phosphate buffer saline (PBS; Solarbio) solution twice a week. The mice were divided into four groups (sh-NC + PBS, sh-circ_0072083 + PBS, sh-NC + TMZ, and sh-circ_0072083 + TMZ; n=5 per group). Tumor volume was measured every 7 days with a formula (0.5 × length × width^2). After 28 days, mice were euthanized, and tumor tissues were weighed and collected for RNA isolation.

Moreover, the exosomes isolated from U251/TR cells stably transfected with sh-NC or sh-circ were termed as U251/TR-sh-NC EXO or U251/TR-sh-circ_0072083 EXO. U251 cells (2 × 10^6 per mouse) were subcutaneously injected into mice. After 7 days, the mice were intraperitoneally injected with 20 mg/kg TMZ and intratumorally injected with 10 μg U251/TR-sh-NC EXO or U251/TR-sh-circ_0072083 EXO or PBS. The mice were divided into three groups (PBS + TMZ, U251/TR-sh-NC EXO + TMZ, and U251/TR-sh-circ_0072083 EXO + TMZ; n=5 per group). Tumor volume was detected, and mice were euthanized after 28 days. Tumor weight was measured, and the tumor tissues were used for RNA or protein isolation.

**Western blot**

Protein was extracted using radioimmunoprecipitation assay buffer (Thermo Fisher Scientific), and concentration was determined with a bicinchoninic acid kit (Beyotime). 20 μg protein was separated via sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred on polyvinylidene fluoride membrane (Bio-Rad). After being blocked in 3% bovine serum albumin (Solarbio), the membranes were interacted with primary antibodies for ALKBH5 (ab244296, 1:2000 dilution, Abcam, Cambridge, UK), NANOG (ab203919, 1:1000 dilution, Abcam), cluster of differentiation (CD) 63 (ab216130, 1:1000 dilution, Abcam), CD81 (ab109201, 1:5000 dilution, Abcam), tumor susceptibility gene 101
(TSG101) (ab125011, 1:2000 dilution, Abcam), Golgi marker 130 (GM130) (ab187514, 1:2000 dilution, Abcam), glucose transporter 1 (GLUT1) (ab128033, 1:3000 dilution, Abcam), lactate dehydrogenase A (LDHA) (ab84716, 1:1000 dilution, Abcam), pyruvate kinase M2 (PKM2) (ab137852, 1:1000 dilution, Abcam) or β-actin (ab179467, 1:5000 dilution, Abcam) overnight and horseradish peroxidase-labeled secondary antibody IgG (ab97080, 1:8000 dilution, Abcam) for 2 h. β-actin functioned as a normalized control. After incubation of enhanced chemiluminescence reagent (Beyotime), the visualized blots were analyzed via Image J v1.8. Relative protein level was expression as fold-change of the control group.

**Exosome isolation, validation, exposure and stability**

Cell medium or serum samples were collected and used for exosome isolation using a total exosome RNA and protein isolation kit (Thermo Fisher Scientific) following the instructions [28]. The exosomes were resuspended in PBS and validated via transmission electron microscopy (TEM) and levels of exosomal markers (CD63, CD81 and TSG101). For TEM analysis, the exosomes were fixed with 5% glutaraldehyde (Sigma) and then observed under a TEM (Hitachi, Tokyo, Japan) after the sample preparation as previously reported [29]. The size distribution and concentration of exosomes were analyzed via ZetaView (Particle Metrix, Ammersee, Germany). The exosomes isolated from U251/TR and U87/TR cells stably transfected with sh-NC or sh-circ_0072083 were termed as U251/TR-sh-NC EXO, U251/TR-sh-circ_0072083 EXO, U87/TR-sh-NC EXO or U87/TR-sh-circ_0072083 EXO. For co-incubation with the sensitive cells, U251 and U87 cells were incubated with 2 μg/mL of exosomes for 24 h. For stability testing, the exosomes from serum were exposed to different conditions, including the incubation for 0, 6, 12 and 24 h, and varying pH values (HCl or NaOH treatment), followed via detection of exosomal circ_0072083 level.

**Warburg effect analysis**

The Warburg effect was investigated via lactate production, glucose uptake and levels of glycolysis key enzymes. 2 × 10^6 cells were collected and lysed, and the lysates were used for detection of lactate production and glucose uptake using the specific lactate assay kit or glucose assay kit (Abcam) according to the instructions of manufacturer. Relative levels of lactate production and glucose uptake were normalized to the control group. The abundances of glycolysis key enzymes (GLUT1, LDHA and PKM2) were detected via qRT-PCR and western blot. To stimulate or block the Warburg effect, U251/TR and U87/TR cells were incubated with 5 ng/mL of TNF-α (stimulus) or 1 μM Shikonin (inhibitor) for 24 h [30]. Cells challenged via PBS were used as controls.

**Bioinformatics analysis, dual-luciferase reporter assay, RNA immunoprecipitation (RIP) and methylated RIP (MeRIP)**

The targets of circ_0072083 were predicted via Circinteractome (http://circinteractome.nia.nih.gov), and the miRNAs that could target NANOG and ALKBH5 were predicted via starBase (http://starbase.sysu.edu.cn). The sequence (…UCCUUC…) of circ_0072083 or 3' UTR of NANOG and ALKBH5 with miR-1252-5p complementary site was cloned into the pGL3 vector (Promega, Madison, WI,
USA), generating the wild-type (WT) luciferase reporter vector WT-circ_0072083, WT-NANOG 3'UTR and WT-ALKBH5 3'UTR. The mutant (MUT) luciferase reporter vectors MUT-circ_0072083, MUT-NANOG 3'UTR and MUT-ALKBH5 3'UTR were constructed via mutating the complementary site of miR-1252-5p. The luciferase reporter vectors and miR-1252-5p mimic or miR-NC were co-transfected into 293T cells (a tool cell line for dual-luciferase reporter assay) for 24 h. The luciferase activity was examined with a luciferase analysis kit (Promega).

RIP analysis was conducted using a Magna RIP kit (Sigma). $1 \times 10^7$ U251/TR and U87/TR cells were lysed, and incubated with 50 μL beads pre-coated with antibodies for argonaute 2 (anti-Ago2) (ab186733, 1:50 dilution, Abcam), anti-ALKBH5 (ab244296, 1:30 dilution, Abcam) or anti-IgG (ab190475, 1:100 dilution, Abcam) for overnight. The enrichment abundances of circ_0072083, miR-1252-5p, NANOG and ALKBH5 on the beads were detected via qRT-PCR. The methylated RNA immunoprecipitation (MeRIP) was performed using N6-methyladenosine (m6A) antibody (ab208577, 1:30 dilution, Abcam), and other procedures were same to RIP analysis. The enrichment level of NANOG was measured by qRT-PCR.

**Statistical analysis**

GraphPad Prism 8 (GraphPad Inc., La Jolla, CA, USA) was used for statistical analysis. The experiments were performed with 3 biological replicates × 3 technical replicates, unless otherwise indicated. Data were expressed as mean ± standard deviation (SD). Overall survival of patients was assessed via Kaplan-Meier plot and log-rank test. The association between exosomal circ_0072083 level and clinicopathologic features of patients was tested via χ² test. The difference was compared by Student $t$-test (for 2 groups) or analysis of variance (ANOVA) followed via Tukey's or Sidak's post hoc test (for multiple groups). It was statistically significant when $P < 0.05$.

**Results**

**circ_0072083 abundance is enhanced in TMZ-resistant glioma tissues and cells**

The TMZ-resistant tissues were confirmed with lower proportion of MGMT promoter methylation than TMZ-sensitive samples (Figure 1A). To explore whether circ_0072083 was involved in TMZ resistance in glioma, we measured the expression change of circ_0072083 in the resistant and sensitive tissues. As displayed in Figure 1B, circ_0072083 abundance was higher in TMZ-resistant tissues (n=36) than that in sensitive tissues (n=33) (Figure 1B). Moreover, we constructed the TMZ-resistant cell lines (U251/TR and U87/TR), which had higher IC50 of TMZ than the sensitive cells (Figure 1C and D). circ_0072083 abundance was increased more than 2-fold in the resistant cells (U251/TR and U87/TR) than sensitive cells (U251 and U87) (Figure 1E). Additionally, the information and structure of circ_0072083 were analyzed. CircView software showed that circ_0072083 was generated via back-splicing of exon 2 to exon 20 of ZFR transcripts (Figure 1F). Furthermore, circ_0072083 was more resistant to Actinomycin D and RNase R than corresponding linear type (ZFR) in the two cell lines, indicating the circular structure of circ_0072083 (Figure 1G and H). In addition, circ_0072083 was mainly expressed in cytoplasm in
U251/TR and U87/TR cells (Figure 1I). To knock down circ_0072083 in cells, three siRNAs (si-circ_0072083#1, si-circ_0072083#2 and si-circ_0072083#3) targeted the splice junction of circ_0072083 were constructed, and their efficacy was confirmed (Figure 1J and K).

**circ_0072083 knockdown reduces TMZ resistance in TMZ-resistant glioma cells**

To study the function of circ_0072083 on TMZ resistance, U251/TR and U87/TR cells were transfected with sh-circ_0072083 or sh-NC. The sh-circ_0072083 for stable transfection was constructed on the basis of the sequence of si-circ_0072083#1 with highest knockdown efficacy. Transfection of sh-circ induced more than 65% reduction of circ_0072083 level in U251/TR and U87/TR cells (Figure 2A). circ_0072083 knockdown evidently decreased the IC50 of TMZ in U251/TR and U87/TR cells (Figure 2B). Next, functional analyses were performed in cells with treatment of TMZ (50 μg/mL). In the presence of TMZ, circ_0072083 silence significantly repressed cell proliferation via decreasing the abilities of proliferation and colony formation (Figure 2C and D). Moreover, circ_0072083 interference clearly increased the apoptosis of U251/TR and U87/TR cells in the presence of TMZ (Figure 2E). In addition, circ_0072083 knockdown markedly impaired the abilities of migration and invasion in the two cell lines challenged via TMZ (Figure 2F-H). Furthermore, the effect of circ_0072083 on TMZ efficacy was investigated in a xenograft model. U251/TR cells transfected with sh-circ_0072083 or sh-NC were used to establish the xenograft model, and then mice were treated via TMZ (20 mg/kg) or PBS. Tumor volume and weight were clearly decreased in sh-circ + TMZ group compared with sh-NC + TMZ group (Figure 2I and J). Additionally, circ_0072083 abundance was significantly reduced in sh-circ_0072083 + TMZ group in comparison to sh-NC + TMZ group (Figure 2K). These results showed that circ_0072083 silence attenuates TMZ resistance in glioma.

**circ_0072083 silence inhibits NANOG level via regulating ALKBH5-mediated demethylation in TMZ-resistant glioma cells**

To explore whether ALKBH5 and NANOG were required via circ_0072083 in regulating TMZ resistance, their levels were detected in TMZ-resistant tissues and cells. As shown in Figure 3A and B, ALKBH5 and NANOG mRNA levels were significantly elevated in TMZ-resistant tissues and cells compared with those in the sensitive group. Moreover, NANOG mRNA m6A level was evidently decreased in TMZ-resistant group in comparison to that in sensitive group (Figure 3C and D). In addition, ALKBH5 and NANOG protein levels were evidently increased in TMZ-resistant tissues and cells (Figure 3E and F). And NANOG expression was markedly reduced via ALKBH5 silence using transfection of sh-ALKBH5 (Figure 3G and H). Furthermore, RIP assay displayed that NANOG could be enriched by ALKBH5 in U251/TR and U87/TR cells (Figure 3I). Additionally, ALKBH5 silence evidently enhanced m6A level of NANOG mRNA and decreased NANOG mRNA stability in response to Actinomycin D (Figure 3J and K). Besides, the effect of circ_0072083 on ALKBH5 and NANOG expression was evaluated in U251/TR and U87/TR cells. Results exhibited that circ_0072083 silence significantly decreased ALKBH5 and NANOG abundances and increased the m6A level of NANOG mRNA (Figure 3L-N). These data indicated that circ_0072083 could regulate NANOG expression via regulating ALKBH5-mediated demethylation.
circ_0072083 interacts with miR-1252-5p to modulate ALKBH5/NANOG axis and TMZ resistance in TMZ-resistant glioma cells

To analyze how circ_0072083 regulate ALKBH5/NANOG axis, the potential miRNA as a crosstalk was explored. Based on the database of Circinteractome and starBase, the Venn diagram showed that only one miRNA (miR-1252-5p) could bind with circ_0072083, ALKBH5 and NANOG (Figure 4A), and the complementary sequences (…UCCUUC…) were displayed in Figure 4B. miR-1252-5p expression was remarkably decreased in TMZ-resistant tissues and cells (Figure 4C and D). To validate their interaction, the wild-type and mutant luciferase reporter vectors were constructed. miR-1252-5p overexpression obviously decreased the luciferase activity in the wild-type group (WT-circ_0072083, WT-NANOG 3'UTR and WT-ALKBH5 3'UTR), while it did not change the activity in the mutant group (MUT-circ_0072083, MUT-NANOG 3'UTR and MUT-ALKBH5 3'UTR) (Figure 4E-G). Moreover, Ago2 RIP assay showed that miR-1252-5p, circ_0072083, ALKBH5 and NANOG could be enriched on the same complex (Figure 4H). In addition, miR-1252-5p level was evidently enhanced via circ_0072083 silence in U251/TR and U87/TR cells (Figure 4I). Furthermore, the effect of miR-1252-5p on ALKBH5 and NANOG levels was analyzed in cells transfected with miR-1252-5p mimic or miR-NC. The efficacy of miR-1252-5p mimic was validated in Supplementary Figure 1. miR-1252-5p overexpression significantly decreased ALKBH5 and NANOG levels in U251/TR and U87/TR cells (Figure 4J and K). Additionally, the effect of circ_0072083/miR-1252-5p axis on ALKBH5 and NANOG levels was investigated in cells transfected with sh-NC + anti-NC, sh-circ_0072083 + anti-NC or sh-circ_0072083 + anti-miR-1252-5p. The efficacy of anti-miR-1252-5p was confirmed in Figure 4L. ALKBH5 and NANOG levels was notably reduced via circ_0072083 silence, which were restored by miR-1252-5p knockdown (Figure 4M and N). Besides, miR-1252-5p knockdown reversed silence of circ_0072083-mediated reduction of IC50 of TMZ, cell proliferation, migration and invasion and promotion of apoptosis in U251/TR and U87/TR cells (Figure 4O-U). These results suggested that circ_0072083 could regulate miR-1252-5p/ALKBH5/NANOG axis to control TMZ resistance in glioma cells.

The secretion of exosomal circ_0072083 is dependent on Warburg effect in TMZ-resistant glioma cells

To explore whether circ_0072083 was carried via exosomes, the exosomes were isolated from medium of TMZ-resistant and sensitive cells. The exosomes were confirmed via TEM in Figure 5A. The size was mainly at 100-200 nm, and resistant cells had higher concentration of exosome than sensitive cells (Figure 5B). Moreover, the exosomes were also identified via the presence of specific markers (CD63, CD81 and TSG101) and absence of Golgiosome marker (GM130) (Figure 5C). Additionally, exosomal circ_0072083 level was evidently elevated in U251/TR and U87/TR cells compared with that in U251 and U87 cells (Figure 5D). Furthermore, higher Warburg effect was found in the resistant cells than sensitive cells, which was revealed via the increased levels of lactate production, glucose uptake and key enzymes (GLUT1, LDHA and PKM2) (Figure 5E-H). In addition, inhibition of Warburg effect (Shikonin) significantly decreased exosome concentration and exosomal circ_0072083 level, but promotion of Warburg effect (TNF-α) played an opposite role (Figure 5I and J). These data indicated that Warburg effect promoted exosomal circ_0072083 expression in TMZ-resistant glioma cells.
Exosomal circ_0072083 from resistant cells promotes TMZ resistance in sensitive glioma cells

To study the function of exosomal circ_0072083 on TMZ resistance, the exosomes were isolated from U251/TR and U87/TR cells transfected with sh-circ_0072083 (U251/TR-sh-circ_0072083 EXO and U87/TR-sh-circ_0072083 EXO) or sh-NC (U251/TR-sh-NC EXO and U87/TR-sh-NC EXO), and incubated with U251 and U87 cells. Exosomal circ_0072083 level was evidently decreased in the medium of U251/TR and U87/TR cells with transfection of sh-circ (Figure 6A). The levels of circ_0072083, ALKBH5 and NANOG were significantly increased and miR-1252-5p expression was reduced in U251 and U87 cells with incubation of U251/TR-sh-NC EXO and U87/TR-sh-NC EXO compared with PBS group, while these events were attenuated via circ_0072083 down-regulation in cells with treatment of U251/TR-sh-circ_0072083 EXO and U87/TR-sh-circ_0072083 EXO (Figure 6B and C). Furthermore, incubation of U251/TR-sh-NC EXO and U87/TR-sh-NC EXO significantly enhanced the IC50 of TMZ in U251 and U87 cells, which was weakened via circ_0072083 knockdown (Figure 6D). Additionally, introduction of U251/TR-sh-NC EXO and U87/TR-sh-NC EXO evidently promoted cell proliferation, migration and invasion and inhibited apoptosis of U251 and U87 cells under treatment of TMZ (50 μg/mL), but these events were relieved by circ_0072083 silence in U251/TR-sh-circ_0072083 EXO and U87/TR-sh-circ_0072083 EXO groups (Figure 6E-K). Moreover, the effect of exosomal circ_0072083 on glioma cell growth in vivo was investigated via U251 cell xenograft model. The xenograft mice were treated via PBS + TMZ (20 mg/kg), U251/TR-sh-NC EXO (10 μg) + TMZ (20 mg/kg), or U251/TR-sh-circ_0072083 EXO (10 μg) + TMZ (20 mg/kg). Tumor volume and weight were clearly increased via addition of U251/TR-sh-NC EXO, which were mitigated by introduction of U251/TR-sh-circ_0072083 EXO (Figure 7A and B). In addition, the abundances of circ_0072083, ALKBH5 and NANOG were evidently enhanced and miR-1252-5p expression was decreased in tumor tissues in U251/TR-sh-NC EXO + TMZ group, and these events were reversed in U251/TR-sh-circ_0072083 EXO + TMZ group (Figure 7C and D). These results indicated that exosomal circ_0072083 increased TMZ resistance in sensitive cells.

Exosomal circ_0072083 is related to TMZ resistance, diagnosis and survival of glioma patients

To analyze the value of exosomal circ_0072083 in glioma patients, the exosomes were isolated from patients’ serum samples. The exosomes were validated via TEM and specific markers (CD63, CD81 and TSG101) (Figure 8A and C). Moreover, the size was mainly at 100-200 nm, and its concentration was higher in resistant patients (Figure 8B). Additionally, exosomal circ_0072083 level was significantly up-regulated in TMZ-resistant patients (n=36) compared with TMZ-sensitive patients (n=33) (Figure 8D). Furthermore, the stability of exosomal circ_0072083 was evaluated via exposing these exosomes to different conditions, and the results showed the abundance of exosomal circ_0072083 in TMZ-resistant patients was not significantly affected via different incubation time and varying pH values (Figure 8E and F). In addition, exosomal circ_0072083 could act as an independent diagnostic target for glioma (area under curve (AUC)=0.85, P<0.05), and patients with high exosomal circ_0072083 level had lower overall survival (P<0.05) (Figure 8G and H). The patients were divided into high (n=36) or low (n=33) exosomal circ_0072083 group according to the mean level. Table 1 summarized that high exosomal circ_0072083 level was associated with tumor size, advanced WHO grade, MGMT methylation and TMZ resistance in
Discussion

Glioma is a type of deadly brain tumor with huge challenge for cure [31]. TMZ chemotherapy is a main strategy for glioma treatment, and the resistance development is a limited factor for its application [32]. Therefore, we wanted to explore new strategies for ameliorating TMZ sensitivity in glioma. The exosomal noncoding RNAs (including exosomal circRNAs) play important roles in the development, treatment and regulation of drug resistance in glioma [6]. In this study, we mainly investigated the promoting effect of exosomal circ_0072083 on TMZ resistance, and validated the regulatory network of circ_0072083/miR-1252-5p/NANOG in glioma.

Liu et al. suggested that circ_0072083 could repress cell proliferation and promote apoptosis by regulating miR-130a/miR-107/phosphatase and tensin homolog (PTEN) in gastric cancer [11]. Moreover, Wei et al. reported that circ_0072083 could contribute to cell proliferation and invasion via regulating miR-1261/C8orf4 axis in papillary thyroid carcinoma [12]. In addition, circ_0072083 could promote cell proliferation, migration and invasion via regulating miR-545-3p/Cbl proto-oncogene like 1 (CBLL1) in non-small cell lung cancer [34]. These reports indicated that circ_0072083 is a multifunctional circRNA in different tumors due to the varying tumor microenvironment. In this study, we found that high expression of circ_0072083 might be associated with TMZ resistance in glioma patients and cell lines. Furthermore, via in vitro and in vivo experiments, we found that circ_0072083 silence inhibited TMZ resistance in glioma, indicating this circRNA might function as a promising target for regulating TMZ treatment in glioma.

NANOG is a stemness regulatory factor, which modulates carcinogenesis and multidrug resistance in malignant tumors [35, 36]. Previous studies suggested that NANOG contributed to the glioma malignancy via promoting cell growth [20, 37]. Additionally, NANOG might be activated via the aberrant Notch signaling to promote tumor recurrence and invasion in glioma [38]. More importantly, multiple evidences have confirmed that NANOG could facilitate TMZ resistance in glioma [19, 39, 40]. Here we found circ_0072083 knockdown could decrease NANOG expression. Thus, we next wanted to explore how circ_0072083 could regulate NANOG. miRNAs could act as a crosstalk for the interaction of circRNA and mRNA [8], and they were associated with TMZ resistance in glioma [3]. miR-1252-5p has been reported as an anti-tumor miRNA [15-17], and is associated with regulation of drug resistance [17]. Our study was the first time to validate miR-1252-5p could interact with circ_0072083 and NANOG, thus resulting in that circ_0072083 could modulate NANOG indirectly via miR-1252-5p to regulate TMZ resistance in glioma.

m6A is also one important mRNA modification in glioma [41]. The m6A demethylase ALKBH5 is one of important factors for TMZ resistance in glioma [42]. Liu et al. reported that ALKBH5 could enhance sex
determining region Y-box2 (SOX2) expression via regulating the demethylation to increase TMZ resistance in glioma [43]. This suggested that ALKBH5 might regulate resistance-related mRNA to control TMZ resistance. Previous studies reported that ALKBH5 could up-regulate NANOG expression via regulating the demethylation of NANOG in different tumors, like breast cancer, oral squamous cell carcinoma and ovarian cancer [24, 44, 45]. Similarly, we also found that ALKBH5 could increase NANOG expression in glioma. Moreover, the m6A modification may be addressed by noncoding RNA [21]. Apart from the direct interaction of miR-1252-5p and 3'UTR of NANOG, we also found that miR-1252-5p could bind with 3'UTR of ALKBH5. Hence, we thought miR-1252-5p could directly target NANOG 3'UTR or inhibit ALKBH5-mediated demethylation to reduce NANOG expression in glioma.

CircRNAs can be carried via exosomes to exhibit their functions to promote or inhibit tumor development [46]. Moreover, exosome release was affected by TMZ treatment in glioma [4]. By isolating the exosomes from cell medium or patients’ serum, we found that circ_0072083 could be carried via exosomes. Multiple evidences showed that the release of exosomes was dependent on the Warburg effect [30, 47, 48]. Similarly, we also identified that the Warburg effect contributed to the transfer of exosomal circ_0072083 in glioma. Exosomes are responsible for the communication in microenvironment in glioma [49]. Here we confirmed that exosomal circ_0072083 from resistant cells might increase the resistance of TMZ to sensitive cell lines. In addition, we found the diagnostic and prognostic values of exosomal circ_0072083 in glioma patients. Collectively, the exosomal circ_0072083 might increase TMZ resistance and act as important target in glioma.

**Conclusions**

In conclusion, exosomal circ_0072083 could promote TMZ resistance in glioma by increasing NANOG, possibly via regulating miR-1252-5p-mediated degradation and miR-1252-5p/ALKBH5 axis-mediated demethylation. This research provides a novel insight into the understanding of TMZ resistance, and indicates a new target for improving TMZ treatment in glioma.

**Abbreviations**

TMZ: Temozolomide; NANOG: Nanog homeobox; circ_0072083: hsa_circ_0072083; ALKBH5: AlkB homolog H5; MGMT: O6-methylguanine-DNA methyltransferase; SOX2: sex determining region Y-box2

**Declarations**

**Acknowledgement**

The authors thank all members for assistance in various aspects of this work.

**Authors’ contributions**
GJJ and DCY designed the study, analyzed the data, and wrote the manuscript. YXH and CXR performed most of the experiments. WZY, YHH and CXY assisted with the generation of reagents and analysis of data. ZGQ, SY and BXY provided glioma tissue samples. WXY, LZY, LYX and KDZ provided reagents and participated in the preparation of the manuscript. All authors provided critical feedback on the manuscript. All authors read and approved the final manuscript.

**Funding**

This work was supported by grants from National Natural Science Foundation of China (No.81901395), Key scientific and technological projects in Henan Province (No. 192102310126) and Henan University Education Development Foundation (No. 2019004).

**Availability of data and materials**

All data in our study are available upon request.

**Ethics approval and consent to participate**

Animal care and use followed the ethical guidelines of the Chinese Council on Animal Care and were reviewed and approved by the Institutional Animal Care and Use Committee.

**Consent for publication**

Consent to publish has been obtained from all authors.

**Competing interests**

The authors declare that they have no conflicts of interest.

**References**

[1] M. Weller, W. Wick, K. Aldape, M. Brada, M. Berger, S.M. Pfister, R. Nishikawa, M. Rosenthal, P.Y. Wen, R. Stupp, G. Reifenberger, Glioma, Nat Rev Dis Primers 1 (2015) 15017.

[2] L.E. Donovan, A.B. Lassman, Chemotherapy Treatment and Trials in Low-Grade Gliomas, Neurosurg Clin N Am 30(1) (2019) 103-109.

[3] S. Jiapaer, T. Furuta, S. Tanaka, T. Kitabayashi, M. Nakada, Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma, Neurol Med Chir (Tokyo) 58(10) (2018) 405-421.

[4] G. Andre-Gregoire, N. Bidere, J. Gavard, Temozolomide affects Extracellular Vesicles Released by Glioblastoma Cells, Biochimie 155 (2018) 11-15.

[5] A. Balasa, G. Serban, R. Chinezu, C. Hurghis, F. Tamas, D. Manu, The Involvement of Exosomes in Glioblastoma Development, Diagnosis, Prognosis, and Treatment, Brain Sci 10(8) (2020).
[6] J. Cheng, J. Meng, L. Zhu, Y. Peng, Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications, Mol Cancer 19(1) (2020) 66.

[7] J. Liu, K. Zhao, N. Huang, N. Zhang, Circular RNAs and human glioma, Cancer Biol Med 16(1) (2019) 11-23.

[8] Y. Yuan, L. Jiaoming, W. Xiang, L. Yanhui, J. Shu, G. Maling, M. Qing, Analyzing the interactions of mRNAs, miRNAs, IncRNAs and circRNAs to predict competing endogenous RNA networks in glioblastoma, J Neurooncol 137(3) (2018) 493-502.

[9] C. Ding, X. Yi, X. Wu, X. Bu, D. Wang, Z. Wu, G. Zhang, J. Gu, D. Kang, Exosome-mediated transfer of circRNA CircNFIIX enhances temozolomide resistance in glioma, Cancer Lett 479 (2020) 1-12.

[10] C. Han, S. Wang, H. Wang, J. Zhang, Exosomal Circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/ZIC5 Axis in Glioma, Cancer Biother Radiopharm (2020).

[11] T. Liu, S. Liu, Y. Xu, R. Shu, F. Wang, C. Chen, Y. Zeng, H. Luo, Circular RNA-ZFR Inhibited Cell Proliferation and Promoted Apoptosis in Gastric Cancer by Sponging miR-130a/miR-107 and Modulating PTEN, Cancer Res Treat 50(4) (2018) 1396-1417.

[12] H. Wei, L. Pan, D. Tao, R. Li, Circular RNA circZFR contributes to papillary thyroid cancer cell proliferation and invasion by sponging miR-1261 and facilitating C8orf4 expression, Biochem Biophys Res Commun 503(1) (2018) 56-61.

[13] B. Banelli, A. Forlani, G. Allemanni, A. Morabito, M.P. Pistillo, M. Romani, MicroRNA in Glioblastoma: An Overview, Int J Genomics 2017 (2017) 7639084.

[14] S.Y. Low, Y.K. Ho, H.P. Too, C.T. Yap, W.H. Ng, MicroRNA as potential modulators in chemoresistant high-grade gliomas, J Clin Neurosci 21(3) (2014) 395-400.

[15] X. Tian, L. Zhang, Y. Jiao, J. Chen, Y. Shan, W. Yang, CircABCB10 promotes nonsmall cell lung cancer cell proliferation and migration by regulating the miR-1252/FOXR2 axis, J Cell Biochem 120(3) (2019) 3765-3772.

[16] Z. Hu, P. Zhao, K. Zhang, L. Zang, H. Liao, W. Ma, Hsa_circ_0011290 regulates proliferation, apoptosis and glycolytic phenotype in papillary thyroid cancer via miR-1252/ FSTL1 signal pathway, Arch Biochem Biophys 685 (2020) 108353.

[17] S. Zhang, J. Cheng, C. Quan, H. Wen, Z. Feng, Q. Hu, J. Zhu, Y. Huang, X. Wu, circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252, Mol Ther Nucleic Acids 19 (2020) 718-730.
[18] C.R. Jeter, T. Yang, J. Wang, H.P. Chao, D.G. Tang, Concise Review: NANOG in Cancer Stem Cells and Tumor Development: An Update and Outstanding Questions, Stem Cells 33(8) (2015) 2381-90.

[19] Z. Wang, J. Yang, G. Xu, W. Wang, C. Liu, H. Yang, Z. Yu, Q. Lei, L. Xiao, J. Xiong, L. Zeng, J. Xiang, J. Ma, G. Li, M. Wu, Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors, Oncotarget 6(5) (2015) 3147-64.

[20] C.D. Cheng, Y.F. Dong, W.X. Niu, C.S. Niu, HAUSP promoted the growth of glioma cells in vitro and in vivo via stabilizing NANOG, Pathol Res Pract 216(4) (2020) 152883.

[21] Y.C. Yi, X.Y. Chen, J. Zhang, J.S. Zhu, Novel insights into the interplay between m(6)A modification and noncoding RNAs in cancer, Mol Cancer 19(1) (2020) 121.

[22] J. Wang, J. Wang, Q. Gu, Y. Ma, Y. Yang, J. Zhu, Q. Zhang, The biological function of m6A demethylase ALKBH5 and its role in human disease, Cancer Cell Int 20 (2020) 347.

[23] S. Zhang, B.S. Zhao, A. Zhou, K. Lin, S. Zheng, Z. Lu, Y. Chen, E.P. Sulman, K. Xie, O. Bogler, S. Majumder, C. He, S. Huang, m(6)A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program, Cancer Cell 31(4) (2017) 591-606 e6.

[24] C. Zhang, D. Samanta, H. Lu, J.W. Bullen, H. Zhang, I. Chen, X. He, G.L. Semenza, Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m(6)A-demethylation of NANOG mRNA, Proc Natl Acad Sci U S A 113(14) (2016) E2047-56.

[25] B. Oldrini, N. Vaquero-Siguero, Q. Mu, P. Kroon, Y. Zhang, M. Galan-Ganga, Z. Bao, Z. Wang, H. Liu, J.K. Sa, J. Zhao, H. Kim, S. Rodriguez-Perales, D.H. Nam, R.G.W. Verhaak, R. Rabadán, T. Jiang, J. Wang, M. Squatrito, MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas, Nat Commun 11(1) (2020) 3883.

[26] M. Kanemoto, M. Shirahata, A. Nakauma, K. Nakanishi, K. Taniguchi, Y. Kukita, Y. Arakawa, S. Miyamoto, K. Kato, Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region, BMC Cancer 14 (2014) 641.

[27] T. Cai, Y. Liu, J. Xiao, Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma, Cancer Med 7(4) (2018) 1404-1415.

[28] B. Yu, Q. Du, H. Li, H. Liu, X. Ye, B. Zhu, Q. Zhai, X. Li, Diagnostic potential of serum exosomal colorectal neoplasia differentially expressed long non-coding RNA (CRNDE-p) and microRNA-217 expression in colorectal carcinoma, Oncotarget 8(48) (2017) 83745-83753.

[29] R. Zheng, M. Du, X. Wang, W. Xu, J. Liang, W. Wang, Q. Lv, C. Qin, H. Chu, M. Wang, L. Yuan, J. Qian, Z. Zhang, Exosome-transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression, Molecular cancer 17(1) (2018) 143.
[30] Y. Wei, D. Wang, F. Jin, Z. Bian, L. Li, H. Liang, M. Li, L. Shi, C. Pan, D. Zhu, X. Chen, G. Hu, Y. Liu, C.Y. Zhang, K. Zen, Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23, Nat Commun 8 (2017) 14041.

[31] K. Aldape, K.M. Brindle, L. Chesler, R. Chopra, A. Gajjar, M.R. Gilbert, N. Gottardo, D.H. Gutmann, D. Hargrave, E.C. Holland, D.T.W. Jones, J.A. Joyce, P. Kearns, M.W. Kieran, I.K. Mellinghoff, M. Merchant, S.M. Pfister, S.M. Pollard, V. Ramaswamy, J.N. Rich, G.W. Robinson, D.H. Rowitch, J.H. Sampson, M.D. Taylor, P. Workman, R.J. Gilbertson, Challenges to curing primary brain tumours, Nat Rev Clin Oncol 16(8) (2019) 509-520.

[32] A. Arora, K. Somasundaram, Glioblastoma vs temozolomide: can the red queen race be won?, Cancer Biol Ther 20(8) (2019) 1083-1090.

[33] H. Zhang, X. Wang, B. Hu, F. Zhang, H. Wei, L. Li, Circular RNA ZFR accelerates non-small cell lung cancer progression by acting as a miR-101-3p sponge to enhance CUL4B expression, Artif Cells Nanomed Biotechnol 47(1) (2019) 3410-3416.

[34] H. Li, F. Liu, W. Qin, Circ_0072083 interference enhances growth-inhibiting effects of cisplatin in non-small-cell lung cancer cells via miR-545-3p/CBLL1 axis, Cancer Cell Int 20 (2020) 78.

[35] O.G. Wong, A.N. Cheung, Stem cell transcription factor NANOG in cancers—is eternal youth a curse?, Expert Opin Ther Targets 20(4) (2016) 407-17.

[36] N. Gawlik-Rzemieniewska, I. Bednarek, The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells, Cancer Biol Ther 17(1) (2016) 1-10.

[37] X.T. Li, J.C. Li, M. Feng, Y.X. Zhou, Z.W. Du, Novel IncRNA-ZNF281 regulates cell growth, stemness and invasion of glioma stem-like U251s cells, Neoplasma 66(1) (2019) 118-127.

[38] J.B. Yu, H. Jiang, R.Y. Zhan, Aberrant Notch signaling in glioblastoma stem cells contributes to tumor recurrence and invasion, Mol Med Rep 14(2) (2016) 1263-8.

[39] L. Zhang, Y. Yan, Y. Jiang, J. Qian, L. Jiang, G. Hu, Y. Lu, C. Luo, Knockdown of SALL4 expression using RNA interference induces cell cycle arrest, enhances early apoptosis, inhibits invasion and increases chemosensitivity to temozolomide in U251 glioma cells, Oncol Lett 14(4) (2017) 4263-4269.

[40] W. Huang, Z. Zhong, C. Luo, Y. Xiao, L. Li, X. Zhang, L. Yang, K. Xiao, Y. Ning, L. Chen, Q. Liu, X. Hu, J. Zhang, X. Ding, S. Xiang, The miR-26a/AP-2alpha/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma, Theranostics 9(19) (2019) 5497-5516.

[41] S. Galardi, A. Michienzi, S.A. Ciafre, Insights into the Regulatory Role of m(6)A Epitranscriptome in Glioblastoma, Int J Mol Sci 21(8) (2020).
[42] K. Bhawe, Q. Felty, C. Yoo, N.Z. Ehtesham, S.E. Hasnain, V.P. Singh, I. Mohapatra, D. Roy, Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma, Mol Neurobiol 57(9) (2020) 3827-3845.

[43] B. Liu, J. Zhou, C. Wang, Y. Chi, Q. Wei, Z. Fu, C. Lian, Q. Huang, C. Liao, Z. Yang, H. Zeng, N. Xu, H. Guo, LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma, Cell Death Dis 11(5) (2020) 384.

[44] O. Shriwas, M. Priyadarshini, S.K. Samal, R. Rath, S. Panda, S.K. Das Majumdar, D.K. Muduly, M. Botlagunta, R. Dash, DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m(6)A-demethylation of FOXM1 and NANOG, Apoptosis 25(3-4) (2020) 233-246.

[45] Y. Jiang, Y. Wan, M. Gong, S. Zhou, J. Qiu, W. Cheng, RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-kappaB pathway, J Cell Mol Med 24(11) (2020) 6137-6148.

[46] X. Geng, X. Lin, Y. Zhang, Q. Li, Y. Guo, C. Fang, H. Wang, Exosomal circular RNA sorting mechanisms and their function in promoting or inhibiting cancer, Oncol Lett 19(5) (2020) 3369-3380.

[47] H. Zhao, L. Yang, J. Baddour, A. Achreja, V. Bernard, T. Moss, J.C. Marini, T. Tudawe, E.G. Seviour, F.A. San Lucas, H. Alvarez, S. Gupta, S.N. Maiti, L. Cooper, D. Peehl, P.T. Ram, A. Maitra, D. Nagrath, Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism, Elife 5 (2016) e10250.

[48] Z. Ma, X. Cui, L. Lu, G. Chen, Y. Yang, Y. Hu, Y. Lu, Z. Cao, Y. Wang, X. Wang, Exosomes from glioma cells induce a tumor-like phenotype in mesenchymal stem cells by activating glycolysis, Stem Cell Res Ther 10(1) (2019) 60.

[49] E.R. Matarredona, A.M. Pastor, Extracellular Vesicle-Mediated Communication between the Glioblastoma and Its Microenvironment, Cells 9(1) (2019).

Tables

Table 1. The correlation between circ_0072083 level and clinicopathological characteristics in glioma patients
| Characteristics          | All patients | Relative circ_0072083 level | P value |
|-------------------------|--------------|-----------------------------|---------|
|                         |              | High | Low                   |         |
| Gender                  |              |      |                      | >0.05   |
| Male                    | 43           | 22   | 21                    |         |
| Female                  | 26           | 14   | 12                    |         |
| Age(years)              |              |      |                      | >0.05   |
| ≥ 50                    | 39           | 20   | 19                    |         |
| <50                     | 30           | 16   | 14                    |         |
| Tumor size(cm)          |              |      |                      | <0.05   |
| ≥ 4                     | 29           | 24   | 5                     |         |
| <4                      | 40           | 12   | 28                    |         |
| IDH1                    |              |      |                      | >0.05   |
| Mutation                | 33           | 20   | 13                    |         |
| Wild type               | 36           | 16   | 20                    |         |
| WHO grade               |              |      |                      | <0.05   |
| I                                | 31           | 6    | 25                    |         |
| II                                | 38           | 30   | 8                     |         |
| MGMT methylated         |              |      |                      | <0.05   |
| Yes                     | 32           | 6    | 26                    |         |
| No                      | 37           | 30   | 7                     |         |
| TMZ-therapy             |              |      |                      | <0.05   |
| TMZ-sensitive           | 33           | 7    | 26                    |         |
| TMZ-resistant           | 36           | 29   | 7                     |         |

Table 2. The primer sequences for qRT-PCR in this study.
| Name            | Sequence (5’-3’)                      | Reverse                        |
|-----------------|--------------------------------------|--------------------------------|
| miR-1252-5p     | GCCGAGagaagggaaaTTgaaT               | AGTGCAGGGTCCGAGGTATT           |
| U6              | GCTCGCTTCGGCAGCACA                   | GAGGTATTCGACACCAGAGGA          |
| circ_0072083    | AAACTACTTTTGTCAABAAATGAT             | GCTGTGGAATCTCAGAAAAGTA         |
| ZFR             | GAGGAGTACTGGCAGACGCG               | GTCAGGACGAGCGAAGGTG            |
| ALKBH5          | AGTTCCAGTCTTCTGCTGCGCC              | AGGAATGTGGCATGGCACG            |
| NANOG           | TCCCCTTAATTGTTGTTGTG                | TTTACGATGCTGGCTGTAGC           |
| GLUT1           | GAACCTCTTCAGCAGGCGGTC              | TCACACTTTGGGAATCAGCCC          |
| LDHA            | CAGGTCCTTGAGAGGGGTCTT               | CTTCAAAACGCCCCCTTCTTCTT       |
| PKM2            | CCCGATCGTGGAGCTGAAG                  | AGGAGTGTCGCCACCTTTTCTG         |
| 18S rRNA        | ACCGTTGAACCCCATCCTGGA               | GCCTCACTAAACCATCCTCAAT        |

Table 3. The oligo sequences for transfection in this study.

| Name            | Sequence (5’-3’)                      |
|-----------------|--------------------------------------|
| si-circ_0072083#1 | CGGCUGGGCAUAAAUUUGAAU                  |
| si-circ_0072083#2 | AGCCGGCGUGGGCAUAAAUUG                  |
| si-circ_0072083#3 | UGGGCAUAAAUUUGAUAUG                   |
| si-NC           | AAGACAUUGUGUGGUCGCCTT                  |
| sh-circ         | GATCCCCGGCTGGGCATAAAATTTGAGATCTCGAGATTC AAATTTATGCCAGCGGCCTTTT |
| sh-ALKBH5       | GATCC ATTTCTTCAAGCCTAAACAGGCACTCGAGTGCC TGTAGGGCTGAAGAT TTTTTG |
| sh-NC           | CCGGGCGCGTAGCGCTAAAATTTTCTC           |
| miR-1252-5p mimic | agaaggaauuagaauuauuu                |
| miR-NC          | CGAUCGCAUCAGCGAUGC                   |
| anti-miR-1252-5p | UAAAUGAAAUCAAUUUUCUUCU               |
| anti-NC         | CUAACGCAUGCAUCAGCUAGC                |